Example: Variation in experience captured through a focus group of patients with cholangiocarcinoma diagnosed with gene mutation FGFR2 fusions, for which there is a targeted therapy.

One woman, whose clinician had been part of the clinical trials, was screened and offered the targeted therapy as a first treatment option rather than the third‐line indication, sparing her surgery and chemotherapy. Another woman was forced to change physicians when hers refused to do the genomic testing, even when all previous interventions had failed; she did have the mutation and received the therapy but said she felt she had lost months of her life and quality of life. A third woman had started the targeted therapy but was afraid of having too much hope―precision medicine is not a cure.